Betamethasone Dipropionate

• CAT Number: A000937
• CAS Number: 5593-20-4
• Molecular Formula: C28H37FO7
• Molecular Weight: 504.59
• Purity: ≥95%
• Synonyms: Diprosone; Diprolene; Diprolene AF; Diproderm; Maxivate
• Target: Vitamin D Related/Nuclear Receptor
• Storage: -20°C
• IUPAC Name: [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
• InChI: 1S/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
• InChIKey: CIWBQSYVNNPZIQ-XYWKZLDCSA-N
• SMILES: CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC

Betamethasone dipropionate (Cat No.: A000937) is a potent synthetic corticosteroid used topically to treat inflammatory skin conditions such as eczema, psoriasis, and dermatitis. It works by suppressing inflammation, immune responses, and itching through inhibition of cytokine production and leukocyte migration. Available in creams, ointments, and lotions, it provides rapid relief from redness, swelling, and irritation. Prolonged use may cause skin thinning, discoloration, or systemic absorption leading to adrenal suppression. It should be used as directed, especially in children and on sensitive skin areas.

Reference

1: Morita A, Muramatsu S, Kubo R, Ikumi K, Sagawa Y, Saito C, Torii K, Nishida E.
Low incidence of hypercalcemia following combined calcipotriol
hydrate/betamethasone dipropionate ointment treatment in Japanese patients with
severe psoriasis vulgaris. J Dermatolog Treat. 2017 Oct 27:1-16. doi:
10.1080/09546634.2017.1398394. [Epub ahead of print] PubMed PMID: 29076379.

2: Patel NU, Felix K, Reimer D, Feldman SR. Calcipotriene/betamethasone
dipropionate for the treatment of psoriasis vulgaris: an evidence-based review.
Clin Cosmet Investig Dermatol. 2017 Sep 29;10:385-391. doi: 10.2147/CCID.S131727.
eCollection 2017. Review. PubMed PMID: 29033598; PubMed Central PMCID:
PMC5628677.

3: Hashim PW, Nia JK, Terrano D, Goldenberg G, Kircik LH. A Comparative Study to
Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With
Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate
0.05% Lotion. J Drugs Dermatol. 2017 Aug 1;16(8):747-752. PubMed PMID: 28809989.

4: Røpke M, Bulai Livideanu C, Kaldate R, Snel A, Paul C. Changes in
interleukin-17A, macrophage-derived chemokine and adiponectin following treatment
of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam:
results from the PSO-ABLE study. Br J Dermatol. 2017 Jul 19. doi:
10.1111/bjd.15814. [Epub ahead of print] PubMed PMID: 28722136.

5: Frieder J, Kivelevitch D, Menter A. Calcipotriene betamethasone dipropionate
aerosol foam in the treatment of plaque psoriasis: a review of the literature.
Ther Deliv. 2017 Aug;8(9):737-746. doi: 10.4155/tde-2017-0058. Epub 2017 Jun 29.
PubMed PMID: 28659016.

6: Takeichi T, Tsukamoto K, Okuno Y, Kojima D, Kono M, Suga Y, Akiyama M. A
combination of low-dose systemic etretinate and topical
calcipotriol/betamethasone dipropionate treatment for hyperkeratosis and itching
in Olmsted syndrome associated with a TRPV3 mutation. J Dermatol Sci. 2017
Oct;88(1):144-146. doi: 10.1016/j.jdermsci.2017.05.012. Epub 2017 May 29. PubMed
PMID: 28587736.

7: Asche CV, Kim M, Feldman SR, Zografos P, Lu M. Budget impact model in
moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and
betamethasone dipropionate foam on per-patient standard of care costs. J Med
Econ. 2017 Sep;20(9):1000-1006. doi: 10.1080/13696998.2017.1339279. Epub 2017 Jun
19. PubMed PMID: 28581873.

8: Paul C, Leonardi C, Menter A, Reich K, Gold LS, Warren RB, Møller A, Lebwohl
M. Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in
Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE
Study. Am J Clin Dermatol. 2017 Aug;18(4):591. doi: 10.1007/s40257-017-0295-8.
PubMed PMID: 28540589.

9: Menter A, Gold LS, Koo J, Villumsen J, Rosén M, Lebwohl M. Fixed-Combination
Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in
Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled
Studies. Skinmed. 2017 Apr 1;15(2):119-124. eCollection 2017. PubMed PMID:
28528605.

10: Paul C, Leonardi C, Menter A, Reich K, Gold LS, Warren RB, Møller A, Lebwohl
M. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with
Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. Am J Clin
Dermatol. 2017 Jun;18(3):405-411. doi: 10.1007/s40257-017-0258-0. Erratum in: Am
J Clin Dermatol. 2017 May 24;:. PubMed PMID: 28236223; PubMed Central PMCID:
PMC5422452.